RenovoRx, Inc. RNXT
1.19 USD -0.12 (-9.16%)
At closeNov 5, 2026, 6:46 PM EST
1.15 -0.04 -3.36%
After hours · Nov 5, 6:46 PM ET
1.13 Day range 1.33
0.701 52-week range 2.59
- YTD
- +41.67%
- 1 year
- +15.53%
News
benzinga.com CORRECTION: RenovoRx Q3 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
benzinga.com RenovoRx Q3 2026 Earnings Call Transcript RenovoRx (NASDAQ:RNXT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.
benzinga.com RenovoRx Q3 Adj. EPS $(0.08) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The…
globenewswire.com RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
globenewswire.com RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
benzinga.com RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
globenewswire.com RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting:…
benzinga.com RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
globenewswire.com RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC Case Series Reports Tumor…
defenseworld.net RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7% RenovoRx, Inc. (NASDAQ: RNXT - Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 673,558 shares, a growth of…
globenewswire.com RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2…
benzinga.com RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
globenewswire.com RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between…
globenewswire.com RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…- benzinga.com RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
globenewswire.com RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the…
marketbeat.com RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and…
marketbeat.com RenovoRx Q2 Earnings Call Highlights RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
zacks.com RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…- benzinga.com RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.
- benzinga.com RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per…
globenewswire.com RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other…
globenewswire.com RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and…
benzinga.com EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
globenewswire.com RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
globenewswire.com RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
globenewswire.com RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
seekingalpha.com RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
globenewswire.com RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
globenewswire.com RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
benzinga.com Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.
benzinga.com RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and…- benzinga.com RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic…
- benzinga.com RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est. RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
- benzinga.com RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate. RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13 to $13.5.- benzinga.com HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a Buy and maintains $3 price target.
- benzinga.com RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum" The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted…
- benzinga.com RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period…
- benzinga.com Earnings Scheduled For March 30, 2026
- benzinga.com RenovoRx Announces $10M At-The-Market Private Placement For Oversubscribed Common Stock And Milestone Warrant Private Placement The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its commercialization efforts for RenovoCath® in 2026 as the Company seeks to increase revenue, reduce…